2025. A LIPOSOMAL CO-DELIVERY SYSTEM FOR DOXORUBICIN AND AN ANTI-PD-L1 NANOBODY SYNERGIZES CHEMO-IMMUNOTHERAPY IN A MURINE COLON CARCINOMA MODEL. Journal of Medical & Health Sciences Review. 2, 4 (Nov. 2025). DOI:https://doi.org/10.65035/3qvcqd73.